Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Ohio State University: Clinical Trials & FDA Approval Profile

Ohio State University (Global / Institutional) sponsors 27 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 16 active protocols (10 recruiting now), 8 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)11.1%
Median Closed Enrollment vs National (145 pts)42 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Ohio State University
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)27
Active Pipeline (Recruiting Now)16 (10)
Completed vs Stopped Early8 / 3 (11.1%)
Median Closed Actual Enrollment42 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Ohio State University
Hospital Research SiteLocationShared Protocols
Ohio State University Comprehensive Cancer CenterColumbus, OH23

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Ohio State University
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07567040Delaying the Onset of Nearsightedness Until Treatment (DONUT) Clinical TrialPhase IIIRECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Ohio State University Wexner Medical Center across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Ohio State University Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI